Adherence can decrease hospitalizations for inflammatory bowel diseases

High-cost biologic therapies are associated with two-fold decrease in hospitalizations

August 21, 2019

Adherence to high-cost biologic therapies are associated with two-fold decrease in hospitalizations for key inflammatory bowel diseases

This study showed that members with Crohn’s disease or ulcerative colitis who were adherent to biologic therapy had approximately two-fold lower odds of hospitalization. Hospitalizations are costly from a direct and indirect cost perspective. To prevent one hospitalization through improved adherence, plans would incur substantial additional biologic therapy cost. It’s important to consider these findings in clinical care programs and as justification in value-based contracting.

Association Between Hospitalization for Crohn’s Disease (CD) or Ulcerative Colitis (UC) and Biologic Drug Therapy Adherence (March 2019)

Related news


April 19, 2024

AMCP 2024: Behind the Research with Prerak Parikh

Parikh, director of medical pharmacy strategy at Prime/MRx, shares the latest on interchangeable biosimilars


April 19, 2024

LISTEN NOW: Live at AMCP Annual 2024 – Digging into managed care pharmacy insights | Pharmacy Friends podcast

In this episode, Prime/MRx clinicians — along with special guests — discuss the hottest topics covered at the Academy of Managed Care Pharmacy (AMCP)'s 2024 Annual Meeting in New Orleans


April 17, 2024

AMCP 2024: Behind the research with YuQian Liu

Ahead of her session with Andy Killpack, Liu — senior director of specialty clinical solutions at Prime/MRx — shares current care management strategies for cell and gene therapy and the future of this exciting frontier